Share-based Payment Arrangement, Expense of MoonLake Immunotherapeutics from 30 Jun 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
MoonLake Immunotherapeutics quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2021 to 30 Sep 2025.
  • MoonLake Immunotherapeutics Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,708,000, a 101% increase year-over-year.
  • MoonLake Immunotherapeutics Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $11,240,596, a 62% increase year-over-year.
  • MoonLake Immunotherapeutics annual Share-based Payment Arrangement, Expense for 2024 was $7,281,596, a 2.5% increase from 2023.
  • MoonLake Immunotherapeutics annual Share-based Payment Arrangement, Expense for 2023 was $7,106,005, a 26% decline from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

MoonLake Immunotherapeutics Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $11,240,596 $3,708,000 +$1,865,000 +101% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $9,375,596 $3,309,000 +$1,481,000 +81% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $7,894,596 $2,290,000 +$613,000 +37% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $7,281,596 $1,933,596 +$328,090 +20% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2025 2024 FY
Q3 2024 $6,953,506 $1,843,000 +$417,349 +29% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $6,536,157 $1,828,000 +$330,339 +22% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $6,205,818 $1,677,000 -$900,187 -35% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $7,106,005 $1,605,506 -$991,018 -38% 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2025 2024 FY
Q3 2023 $8,097,023 $1,425,651 -$1,159,509 -45% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $9,256,532 $1,497,661 -$986,562 -40% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $10,243,094 $2,577,187 +$588,316 +30% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $9,654,778 $2,596,524 01 Oct 2022 31 Dec 2022 10-K 26 Feb 2025 2024 FY
Q3 2022 $2,585,160 +$729,333 +39% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $2,484,223 +$1,233,858 +99% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $1,988,871 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q3 2021 $1,855,827 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $1,250,365 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2022 2022 Q2

MoonLake Immunotherapeutics Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $7,281,596 +$175,591 +2.5% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2025 2024 FY
2023 $7,106,005 -$2,548,773 -26% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2025 2024 FY
2022 $9,654,778 01 Jan 2022 31 Dec 2022 10-K 26 Feb 2025 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.